title: NCCN Task Force Report: Bone Health In Cancer Care.
abstract: Bone health and maintenance of bone integrity are important components of comprehensive cancer care. Many patients with cancer are at risk for therapy-induced bone loss, with resultant osteoporotic fractures, or skeletal metastases, which may result in pathologic fractures, hypercalcemia, bone pain, and decline in motility and performance status. Effective screening and timely interventions are essential for reducing bone-related morbidity. Management of long-term bone health requires a broad knowledge base. A multidisciplinary health care team may be needed for optimal assessment and treatment of bone-related issues in patients with cancer. Since publication of the previous NCCN Task Force Report: Bone Health in Cancer Care in 2009, new data have emerged on bone health and treatment, prompting NCCN to convene this multidisciplinary task force to discuss the progress made in optimizing bone health in patients with cancer. In December 2012, the panel members provided didactic presentations on various topics, integrating expert judgment with a review of the key literature. This report summarizes issues surrounding bone health in cancer care presented and discussed during this NCCN Bone Health in Cancer Care Task Force meeting.
authors.forename: Julie R
authors.initials: JR
authors.lastname: Gralow
authors.forename: J Sybil
authors.initials: JS
authors.lastname: Biermann
authors.forename: Azeez
authors.initials: A
authors.lastname: Farooki
authors.forename: Monica N
authors.initials: MN
authors.lastname: Fornier
authors.forename: Robert F
authors.initials: RF
authors.lastname: Gagel
authors.forename: Rashmi
authors.initials: R
authors.lastname: Kumar
authors.forename: Georgia
authors.initials: G
authors.lastname: Litsas
authors.forename: Rana
authors.initials: R
authors.lastname: McKay
authors.forename: Donald A
authors.initials: DA
authors.lastname: Podoloff
authors.forename: Sandy
authors.initials: S
authors.lastname: Srinivas
authors.forename: Catherine H
authors.initials: CH
authors.lastname: Van Poznak
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D015519:Bone Density; D001842:Bone and Bones / Q000503:physiopathology*; D002118:Calcium / Q000008:administration & dosage; D019587:Dietary Supplements; D006801:Humans; D020360:Neoadjuvant Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D010024:Osteoporosis / Q000139:chemically induced / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology*; D018570:Risk Assessment; D014807:Vitamin D / Q000008:administration & dosage
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014807:Vitamin D; D002118:Calcium